International Clinical Psychopharmacology最新文献

筛选
英文 中文
Comparative analysis of third-generation antipsychotics in first-episode schizophrenia: efficacy, safety, and cognitive impacts. A narrative review. 第三代抗精神病药物对首发精神分裂症的比较分析:疗效、安全性和认知影响。叙述性综述。
IF 2.1 3区 医学
International Clinical Psychopharmacology Pub Date : 2025-07-01 Epub Date: 2024-06-14 DOI: 10.1097/YIC.0000000000000559
Valerio Ricci, Alessandro Sarni, Giovanni Martinotti, Giuseppe Maina
{"title":"Comparative analysis of third-generation antipsychotics in first-episode schizophrenia: efficacy, safety, and cognitive impacts. A narrative review.","authors":"Valerio Ricci, Alessandro Sarni, Giovanni Martinotti, Giuseppe Maina","doi":"10.1097/YIC.0000000000000559","DOIUrl":"10.1097/YIC.0000000000000559","url":null,"abstract":"<p><strong>Background and objectives: </strong>Schizophrenia is a chronic, complex mental health disorder requiring effective management to mitigate its broad personal and societal impacts. This narrative review assesses the efficacy, effectiveness, and side effects of third-generation antipsychotics (TGAs) like aripiprazole, brexpiprazole, and cariprazine, focusing on their use in first-episode schizophrenia. These drugs aim to reduce side effects typical of earlier antipsychotics while more effectively addressing positive and cognitive symptoms.</p><p><strong>Methods: </strong>Our extensive literature review, using PubMed and Scopus , includes randomized controlled trials and observational studies, showing TGAs may match older antipsychotics in efficacy with fewer side effects, notably in reducing extrapyramidal symptoms and enhancing cognitive outcomes.</p><p><strong>Results: </strong>Aripiprazole appears effective in both acute and maintenance phases of schizophrenia, while brexpiprazole and cariprazine show potential in managing negative symptoms and improving social functioning, essential for patient recovery.</p><p><strong>Conclusions: </strong>This review emphasizes the need for personalized treatment and further research to fully determine the long-term benefits and safety of TGAs. These findings can inform clinical decisions and underline the ongoing need for innovation in schizophrenia pharmacotherapy.</p>","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"191-206"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The specific anti-hostility effect of lurasidone in patients with an acute exacerbation of schizophrenia: results of pooled post hoc analyses in adolescents and adults. 鲁拉西酮对精神分裂症急性加重期患者的特异性抗敌意作用:对青少年和成人的汇总后分析结果。
IF 2.1 3区 医学
International Clinical Psychopharmacology Pub Date : 2025-07-01 Epub Date: 2024-07-22 DOI: 10.1097/YIC.0000000000000563
Leslie Citrome, Elena Álvarez-Barón, Irene Gabarda-Inat, Karthinathan Thangavelu, Michael Tocco
{"title":"The specific anti-hostility effect of lurasidone in patients with an acute exacerbation of schizophrenia: results of pooled post hoc analyses in adolescents and adults.","authors":"Leslie Citrome, Elena Álvarez-Barón, Irene Gabarda-Inat, Karthinathan Thangavelu, Michael Tocco","doi":"10.1097/YIC.0000000000000563","DOIUrl":"10.1097/YIC.0000000000000563","url":null,"abstract":"<p><p>Symptoms of hostility in patients during acute exacerbations of schizophrenia have been associated with aggressive behavior. Data suggest that some second-generation antipsychotics have specific anti-hostility effects, independent of sedation and positive symptom improvement. Two post hoc analyses were performed to examine the efficacy of lurasidone for reducing hostility in patients with schizophrenia. One analysis pooled adults ( N  = 1168) from 5 placebo-controlled, 6-week trials of lurasidone (40-160 mg). Another analysis pooled younger patients (up to age 25 years, N  = 427) from the adult studies and a similarly designed trial of lurasidone (40 or 80 mg) in adolescent patients (13-17 years old). The outcome measure was mean change in the hostility item (P7) of the Positive and Negative Syndrome Scale (PANSS). To address pseudospecificity, results were adjusted for positive symptom change and sedation. In adults with a baseline PANSS hostility score ≥2, significant improvement in hostility was observed for all doses with a dose-related increase in effect size (Cohen's d): lurasidone 40 mg = 0.18, 80 mg = 0.24, 120 mg = 0.36, and 160 mg = 0.53. The same dose-response pattern was observed for the more severe hostility subgroups (P7: ≥3, ≥4), and in the early-onset population. Results suggest that lurasidone has specific, dose-related anti-hostility effects.</p>","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"214-223"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19 and psychiatric disorders among young people: a cross-sectional study. COVID-19 与青少年精神障碍:一项横断面研究。
IF 2.1 3区 医学
International Clinical Psychopharmacology Pub Date : 2025-07-01 Epub Date: 2024-08-22 DOI: 10.1097/YIC.0000000000000565
Tiziano Prodi, Filippo Dragogna, Beatrice Benatti, Alberto Varinelli, Simone Vanzetto, Letizia Gianfelice, Bernardo Dell'Osso
{"title":"COVID-19 and psychiatric disorders among young people: a cross-sectional study.","authors":"Tiziano Prodi, Filippo Dragogna, Beatrice Benatti, Alberto Varinelli, Simone Vanzetto, Letizia Gianfelice, Bernardo Dell'Osso","doi":"10.1097/YIC.0000000000000565","DOIUrl":"10.1097/YIC.0000000000000565","url":null,"abstract":"<p><p>During the COVID-19 pandemic, a significant rise in mental health issues was observed. Particularly, children and adolescents have shown a higher risk of developing mental disorders than adults. This study aimed to describe the evolving features of the requests for psychiatric emergency interventions during the COVID-19 pandemic in young people. We conducted a cross-sectional study comparing the number, characteristics, and symptoms of people aged between 12 and 18 years old attending one Emergency Department (ED) for psychiatric issues, considering three different periods: T0 (8 March 2019-7 March 2020), T1 (8 March 2020-7 March 2021), and T2 (8 March 2021-7 March 2022). Total admissions were 220: 99 (45%) during T0, 40 (18.1%) for T1, and 81 (36.8%) for T2 ( P  < 0.001). A significant decrease in the mean age from T0 to T1 was found ( P  < 0.01). Admissions for psychomotor agitation decreased, while admission due to anxiety disorder and nonsuicidal self-injury raised significantly ( P  < 0.05), as for first psychiatric presentation ( P  < 0.01). Regarding substance use, a significant reduction was observed ( P  < 0.05). The rates of eating disorders ( P  < 0.001) and early insomnia ( P  < 0.01) increased from T0. These findings highlight the worsening of psychiatric symptoms in the young population during the COVID-19 pandemic.</p>","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"224-231"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141909852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk of corrected QT interval prolongation in patients receiving antipsychotics. 接受抗精神病药物治疗的患者出现校正 QT 间期延长的风险。
IF 2.1 3区 医学
International Clinical Psychopharmacology Pub Date : 2025-07-01 Epub Date: 2024-07-31 DOI: 10.1097/YIC.0000000000000564
Juan Carlos Rivas, Juliana Galindo-A, Luis Fernando Zambrano, Carlos Alberto Miranda-B, Sandra Milena Ramírez, Ana María Rivas-Grajales, Mauricio Hernández-Carrillo, Erika Andrea Rincón, Pablo Eduardo Perafán, Juan Esteban Gómez-Mesa
{"title":"Risk of corrected QT interval prolongation in patients receiving antipsychotics.","authors":"Juan Carlos Rivas, Juliana Galindo-A, Luis Fernando Zambrano, Carlos Alberto Miranda-B, Sandra Milena Ramírez, Ana María Rivas-Grajales, Mauricio Hernández-Carrillo, Erika Andrea Rincón, Pablo Eduardo Perafán, Juan Esteban Gómez-Mesa","doi":"10.1097/YIC.0000000000000564","DOIUrl":"10.1097/YIC.0000000000000564","url":null,"abstract":"<p><p>Antipsychotic (AP) use has been associated to QT interval prolongation on the surface electrocardiogram (ECG). Our study aimed to determine the incidence of corrected QT (QTc) interval prolongation among patients admitted to a psychiatric hospitalization unit requiring AP treatment and to assess the relationship between administered dose and QTc interval changes. We enrolled 179 patients admitted to the Hospital Psiquiátrico Departamental Universitario del Valle in Cali, Colombia. ECGs were conducted upon admission, and again at 3 and 7 days postadmission. The QT interval was measured, and QTc interval correction was performed using Bazzet's formula. QTc interval prolongation at time points B or C was observed in 9.5% of patients. Clozapine was the most common AP associated with QTc interval prolongation (20.59%), followed by olanzapine (15.38%). The relative risk of QT interval prolongation with clozapine compared to haloperidol was 4.17 (95% confidence interval, 1.14-15.17, P  = 0.02). AP use upon hospital admission was linked to early (within 3 days) QTc interval prolongation. Clozapine and olanzapine were associated with a greater increase in QTc interval compared to haloperidol, indicating a need for rigorous electrocardiographic monitoring with their use.</p>","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"207-213"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141855386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment adherence rates across different psychiatric disorders and settings: findings from a large patient cohort. 不同精神疾病和环境下的治疗依从率:一个大型患者队列的研究结果。
IF 2.1 3区 医学
International Clinical Psychopharmacology Pub Date : 2025-07-01 Epub Date: 2024-05-30 DOI: 10.1097/YIC.0000000000000557
Nicolaja Girone, Maddalena Cocchi, Francesco Achilli, Edoardo Grechi, Chiara Vicentini, Beatrice Benatti, Matteo Vismara, Alberto Priori, Bernardo Dell'Osso
{"title":"Treatment adherence rates across different psychiatric disorders and settings: findings from a large patient cohort.","authors":"Nicolaja Girone, Maddalena Cocchi, Francesco Achilli, Edoardo Grechi, Chiara Vicentini, Beatrice Benatti, Matteo Vismara, Alberto Priori, Bernardo Dell'Osso","doi":"10.1097/YIC.0000000000000557","DOIUrl":"10.1097/YIC.0000000000000557","url":null,"abstract":"<p><p>Approximately 50% of patients with psychiatric disorders do not fully adhere to the prescribed psychopharmacological therapy, significantly impacting the progression of the disorder and the patient's quality of life. The present study aimed to assess potential differences in terms of rates and clinical features of treatment adherence in a large cohort of psychiatric patients with different diagnoses attending various psychiatric services. The study included 307 psychiatric patients diagnosed with a primary major depressive disorder, bipolar disorder, anxiety disorder, schizophrenic spectrum disorder, or personality disorder. Patient's adherence to treatment was evaluated using the Clinician Rating Scale, with a cutoff of at least five defining adherence subgroups. One-third of the sample reported poor medication adherence. A lower rate of adherence emerged among patients with schizophrenic spectrum disorder and bipolar disorder. Subjects with poor adherence were more frequently inpatients and showed higher current substance use, a greater number of previous hospitalizations, and more severe scores at psychopathological assessment compared with patients with positive adherence. Poor adherence was associated with symptom severity and increased rates of relapses and rehospitalizations. In addition, substance use appears to be an unfavorable transdiagnostic factor for treatment adherence.</p>","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"232-241"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141175639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of clinical outcomes in patients with inflammatory arthritis: analysis from the UK Medical Cannabis Registry. 炎症性关节炎患者的临床疗效评估:英国医用大麻登记处的分析。
IF 2.1 3区 医学
International Clinical Psychopharmacology Pub Date : 2025-07-01 Epub Date: 2024-07-02 DOI: 10.1097/YIC.0000000000000556
Ann Francis, Simon Erridge, Carl Holvey, Ross Coomber, Rahul Guru, Alia Darweish Medniuk, Mohammed Sajad, Robert Searle, Azfer Usmani, Sanjay Varma, James Rucker, Michael Platt, Wendy Holden, Mikael H Sodergren
{"title":"Assessment of clinical outcomes in patients with inflammatory arthritis: analysis from the UK Medical Cannabis Registry.","authors":"Ann Francis, Simon Erridge, Carl Holvey, Ross Coomber, Rahul Guru, Alia Darweish Medniuk, Mohammed Sajad, Robert Searle, Azfer Usmani, Sanjay Varma, James Rucker, Michael Platt, Wendy Holden, Mikael H Sodergren","doi":"10.1097/YIC.0000000000000556","DOIUrl":"10.1097/YIC.0000000000000556","url":null,"abstract":"<p><p>The aim of this study was to assess changes in validated patient-reported outcome measures after initiation of cannabis-based medicinal products (CBMPs) and the safety of CBMPs in patients with inflammatory arthritis. A prospective case series from the UK Medical Cannabis Registry was analyzed. The primary outcomes changes were in Brief Pain Inventory, McGill Pain Questionnaire, EuroQol 5-dimension 5-level (EQ-5D-5L), Generalised Anxiety Disorder-7 questionnaire, and Single-Item Sleep Quality Scale at 1, 3, 6, and 12 months of follow-up compared with baseline. Adverse events were analyzed in accordance with Common Terminology Criteria for Adverse Events, v.4.0. Statistical significance was defined as a P -value less than 0.050. Eighty-two patients met the inclusion criteria. Initiation of CBMP treatment was associated with improvements in Brief Pain Inventory, McGill Pain Questionnaire, EQ-5D-5L, Generalised Anxiety Disorder-7 questionnaire, and Single-Item Sleep Quality Scale at 1, 3, 6, and 12 months compared with baseline ( P  < 0.050). There were 102 (44.35%) mild adverse events, 97 (42.17%) moderate adverse events, and 31 (13.48%) severe adverse events recorded by 21 (25.61%) participants. This study suggests that CBMP treatment is associated with pain improvement and increased health-related quality of life for inflammatory arthritis patients. While causality cannot be inferred in this observational study, the results support the development of randomized control trials for inflammatory arthritis pain management with CBMPs.</p>","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"242-249"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Innovations and challenges in antipsychotic treatments and external modulating factors. 抗精神病药物治疗和外部调节因素的创新与挑战。
IF 2.1 3区 医学
International Clinical Psychopharmacology Pub Date : 2025-07-01 Epub Date: 2025-05-28 DOI: 10.1097/YIC.0000000000000593
Alessandro Serretti
{"title":"Innovations and challenges in antipsychotic treatments and external modulating factors.","authors":"Alessandro Serretti","doi":"10.1097/YIC.0000000000000593","DOIUrl":"https://doi.org/10.1097/YIC.0000000000000593","url":null,"abstract":"","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":"40 4","pages":"187-190"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144158426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Raising awareness for adult ADHD diagnosis: addressing diagnostic challenges, comorbidities, and the path to proper recognition. 提高对成人ADHD诊断的认识:解决诊断挑战、合并症和正确认识的途径。
IF 2.1 3区 医学
International Clinical Psychopharmacology Pub Date : 2025-07-01 Epub Date: 2025-05-28 DOI: 10.1097/YIC.0000000000000570
Camilla Elefante, Giulio Perugi
{"title":"Raising awareness for adult ADHD diagnosis: addressing diagnostic challenges, comorbidities, and the path to proper recognition.","authors":"Camilla Elefante, Giulio Perugi","doi":"10.1097/YIC.0000000000000570","DOIUrl":"https://doi.org/10.1097/YIC.0000000000000570","url":null,"abstract":"","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":"40 4","pages":"250-252"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144158430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Agranulocytosis after long-term clozapine use: a case report. 长期使用氯氮平后粒细胞缺乏症1例。
IF 2.1 3区 医学
International Clinical Psychopharmacology Pub Date : 2025-05-27 DOI: 10.1097/YIC.0000000000000594
Agostina Secchi, Madelaine Bridges, Eromona Whiskey, Sukhi Shergill
{"title":"Agranulocytosis after long-term clozapine use: a case report.","authors":"Agostina Secchi, Madelaine Bridges, Eromona Whiskey, Sukhi Shergill","doi":"10.1097/YIC.0000000000000594","DOIUrl":"https://doi.org/10.1097/YIC.0000000000000594","url":null,"abstract":"<p><p>Neutropenia and the more severe, potentially life-threatening agranulocytosis are recognized side effects of clozapine that require regular, mandatory, and life-long blood monitoring. However, most cases of haematological adverse effects occur in the first few months of treatment; therefore, there are now increasing calls for the termination of the mandatory monitoring after this initial period. In this report, we present a patient with treatment-resistant schizophrenia who was successfully treated with clozapine yet developed neutropenia after 9 years. This soon evolved into agranulocytosis requiring the use of granulocyte colony-stimulating factor and eventual clozapine cessation. Such late-onset cases of agranulocytosis are isolated and rare but should not impede the drive to relax mandatory clozapine haematological monitoring, but patients and carers must be aware of potential symptoms of agranulocytosis.</p>","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risperidone as an adjuvant treatment for obsessive-compulsive symptoms in patients with bipolar disorder: a randomized, double-blind, placebo-controlled clinical trial. 利培酮作为双相情感障碍患者强迫症症状的辅助治疗:一项随机、双盲、安慰剂对照的临床试验
IF 2.1 3区 医学
International Clinical Psychopharmacology Pub Date : 2025-05-21 DOI: 10.1097/YIC.0000000000000592
Ali Sahraian, Mahsa Ghavipisheh, Leila Razeghian Jahromi, Iman Ahrari, Arash Mowla
{"title":"Risperidone as an adjuvant treatment for obsessive-compulsive symptoms in patients with bipolar disorder: a randomized, double-blind, placebo-controlled clinical trial.","authors":"Ali Sahraian, Mahsa Ghavipisheh, Leila Razeghian Jahromi, Iman Ahrari, Arash Mowla","doi":"10.1097/YIC.0000000000000592","DOIUrl":"https://doi.org/10.1097/YIC.0000000000000592","url":null,"abstract":"<p><p>Treatment of obsessive-compulsive disorder (OCD) symptoms in patients with bipolar disorder (BD) is challenging. In this research, the therapeutic effects of risperidone on OCD symptoms in patients with BD are investigated. Forty-two patients with concurrent BD and OCD symptoms were randomly assigned to receive risperidone or a placebo in a blinded randomized placebo-controlled trial. The patients of both groups were in the euthymic phase of BD. OCD symptoms were measured by the Yale-Brown Obsessive Compulsive Behavior Scale (YBOCS) before the study initiation and at the 4th,8th, and 12th weeks in each group. All the patients completed the trial with no dropouts. At the initial evaluation, the risperidone and placebo groups did not differ significantly regarding their YBOCS scores. After 12 weeks of treatment, the OCD symptoms were significantly lower in the risperidone group compared to the placebo group [YBOCS: 5(3) vs. 11(6.5), P-value < 0.001]. The number of patients with more than 35% reduction in YBOCS was significantly higher in the risperidone group compared to the placebo group [20/21 (95.23%) vs. 10/21 (47.61%), P-value = 0.001]. Risperidone could effectively reduce OCD symptoms in BD patients. The treatment was safe and well tolerated.</p>","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信